Relief for Amylyx as FDA clears controversial ALS drug Relyvrio
pharmaphorum
SEPTEMBER 30, 2022
Patient organisations have been celebrating the FDA approval yesterday of Amylyx’ amyotrophic lateral sclerosis (ALS) therapy Relyvrio, after not one but two advisory committee meetings that arrived at different conclusions about the drug.
Let's personalize your content